Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.

ABSTRACT:

Introduction

Triple-negative breast cancer (TNBC) is considered the most aggressive type of breast cancer (BC) with limited options for therapy. TNBC is a heterogeneous disease and tumors have been classified into TNBC subtypes using gene expression profiling to distinguish basal-like 1, basal-like 2, immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen receptor (LAR), and one nonclassifiable group (called unstable).

Objectives

The aim of this study was to verify the clinical relevance of molecular subtyping of TNBCs to improve the individual indication of systemic therapy.

Patients and methods

Molecular subtyping was performed in 124 (82%) of 152 TNBC tumors that were obtained from a prospective, multicenter cohort including 1,270 histopathologicall

SUBMITTER: Hartung C 

PROVIDER: S-EPMC8740062 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature